Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002874 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
NCT00002874 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 840 participants.
The verdict
NCT00002874, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if radiation therapy is more effective with or without bicalutamide for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide in treating patients who have stage II or stage III prostate cancer and elevated prostate-specific antigen (PSA) levels following radical prostatectomy.
Interventions
- DRUG placebo
- RADIATION radiation therapy
- DRUG bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 1998-02 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002874
The ClinicalTrials.gov registry entry for NCT00002874 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00002874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002874 about?
NCT00002874 is a clinical study titled "Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if radiation therapy is more effective wi...
What is the current status of trial NCT00002874?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 1998-02. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT00002874?
The interventions under investigation include: placebo (DRUG), radiation therapy (RADIATION), bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00002874?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.